Skip to main content
. 2006 Aug;118(4):461–471. doi: 10.1111/j.1365-2567.2006.02387.x

Table 2.

Oligoclonal public T-cell expansions and polyclonal positive expansions in the peripheral repertoire from individual transplanted TAP1–/– mice*

Mice with positive expansions after in vitro stimulation with H-2Kb peptides

Mice tested with each peptide

BV-BJ rearrangements (CDR3 size) Mice with positive expansions† Mice with oligoclonal expansions‡ Mice with polyclonal expansions§ 1 2 3 4 5 Profile
BV5S1/BJ1S1 4/5 0/4 4/4 0/3 0/2 0/3 ND 0/5 O
(7 aa) 80% 0% 100% 1/2 3/5 P
BV5S1/BJ1S2 5/5 3/5 2/5 0/3 0/4 3/5 1/5 1/5 O
(7 aa) 100% 60% 40% 2/4 1/5 3/5 3/5 P
BV5S1/BJ1S5§ 3/5 2/3 1/3 ND 1/2 0/4 1/5 2/5 O
(8 aa) 60% 67% 33% 0/2 1/4 1/5 0/5 P
BV5S1/BJ2S4 5/5 5/5 0/5 1/3 4/4 2/4 5/5 2/4 O
(8 aa) 100% 100% 0% 2/3 0/4 2/4 0/5 0/4 P
BV6/BJ1S2 5/5 3/5 2/5 0/5 ND ND 3/5 ND O
(6 aa) 100% 60% 40% 2/5 2/5 P
BV6/BJ2S4 3/4 0/3 3/3 0/4 ND ND ND ND O
(5 aa) 75% 0% 100% 3/4 P
BV9/BJ2S1 5/5 1/5 4/5 1/5 ND ND ND 1/5 O
(4 aa) 100% 20% 80% 1/5 3/5 P
BV11/BJ1S3 5/5 1/5 4/5 1/4 0/2 1/5 ND ND O
(9 aa) 100% 20% 80% 1/4 2/2 1/5 P

Bold font indicates dominant oligoclonal expansions.

The ratios shown are the number of mice with positive expansions in relation to the number of studied animals.

*

Significant BV-BJ expansions detected in the pool from transplanted animals were also analysed in five transplanted TAP1–/– mice. Note that not all animals were studied for all peptides, because of limitations of the biological material.

†

For this analysis, we considered the animals with positive expansion in response to at least one H-2Kb peptide.

‡

For this analysis, we considered the animals with dominant oligoclonal expansions in response to at least one H-2Kb peptide.

§

For this analysis, we considered the animals with positive expansions inside a polyclonal profile in response to at least one H-2Kb peptide.

Oligoclonal expansions present in transplanted TAP1–/– mice ex vivo without in vitro stimulation with peptides.BV-BJ, V-beta–J-beta; CDR, complementarity determining region; ND, not done; O, oligoclonal profiles; P, polyclonal profiles.